Marginal zone lymphoma: present status and future perspectives

Chan Y Cheah¹, Emanuele Zucca², Davide Rossi³, Thomas M Habermann⁴

Affiliations

¹ Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia; Medical School, University of Western Australia, Crawley, Western Australia, Australia. chan.cheah@health.wa.gov.au.
² Oncology Institute of Southern Switzerland, University of Bern and International Extranodal Lymphoma Study Group, Director of Operation Office, Bern, Switzerland.
³ Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
⁴ Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA.

PMID: 34985232
PMCID: PMC8719063
DOI: 10.3324/haematol.2021.278755

Marginal zone lymphoma: present status and future perspectives

Chan Y Cheah et al. Haematologica. 2022.

. 2022 Jan 1;107(1):35-43.

doi: 10.3324/haematol.2021.278755.

Authors

Chan Y Cheah¹, Emanuele Zucca², Davide Rossi³, Thomas M Habermann⁴

Affiliations

¹ Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia; Medical School, University of Western Australia, Crawley, Western Australia, Australia. chan.cheah@health.wa.gov.au.
² Oncology Institute of Southern Switzerland, University of Bern and International Extranodal Lymphoma Study Group, Director of Operation Office, Bern, Switzerland.
³ Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
⁴ Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA.

PMID: 34985232
PMCID: PMC8719063
DOI: 10.3324/haematol.2021.278755

No abstract available

PubMed Disclaimer

Figures

**Figure 1.**
**Mechanism of action of selected novel agents for the treatment of marginal zone lymphoma.** Bold type indicates approved agents, normal type indicates agents under investigation. IgH: immunoglobulin heavy chain; CD: cluster of differentiation; Syk: spleen tyrosine kinase; Btk: Bruton tyrosine kinase; PLCγ2: phospholipase Cγ2; PKCb: protein kinase Cb; PI3K: phosphatidylinositol-3-kinase; Akt: protein kinase B; bax: B-cell lymphoma-2 associated X protein; Bcl2: B-cell lymphoma protein-2; CAR: chimeric antigen receptor; PD-1, programmed cell death-1. Adapted from Cheah *et al.* J Clin Oncol 2016.

See this image and copyright information in PMC

Cited by

Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [¹⁸F]FDG.
Kosmala A, Duell J, Schneid S, Serfling SE, Higuchi T, Weich A, Lapa C, Hartrampf PE, Raderer M, Einsele H, Buck AK, Topp MS, Schlötelburg W, Werner RA. Kosmala A, et al. Eur J Nucl Med Mol Imaging. 2024 Feb;51(3):749-755. doi: 10.1007/s00259-023-06489-6. Epub 2023 Nov 9. Eur J Nucl Med Mol Imaging. 2024. PMID: 37943339 Free PMC article.
Molecular Mechanisms in the Transformation from Indolent to Aggressive B Cell Malignancies.
Maher N, Mouhssine S, Matti BF, Alwan AF, Gaidano G. Maher N, et al. Cancers (Basel). 2025 Mar 6;17(5):907. doi: 10.3390/cancers17050907. Cancers (Basel). 2025. PMID: 40075754 Free PMC article. Review.
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.
Opat S, Tedeschi A, Hu B, Linton KM, McKay P, Leitch S, Coleman M, Zinzani PL, Jin J, Sun M, Sobieraj-Teague M, Browett P, Ke X, Thieblemont C, Ardeshna K, Bijou F, Walker P, Hawkes EA, Ho SJ, Zhou K, Liang Z, Xu J, Tankersley C, Delarue R, Co M, Trotman J. Opat S, et al. Blood Adv. 2023 Nov 28;7(22):6801-6811. doi: 10.1182/bloodadvances.2023010668. Blood Adv. 2023. PMID: 37682792 Free PMC article. Clinical Trial.
Brentuximab vedotin therapy followed by autologous peripheral stem cell transplantation as a viable treatment option for an older adult with transformed lymphoma: a case report and literature review.
Tan J, Zhong J, Hu W, Wu G, Zeng C, Xiong D. Tan J, et al. J Int Med Res. 2024 Jun;52(6):3000605241258597. doi: 10.1177/03000605241258597. J Int Med Res. 2024. PMID: 38869106 Free PMC article. Review.
Marginal Zone Lymphoma in a Case of Hidradenitis Suppurativa Treated With Adalimumab Therapy.
Shrestha AK, Pokherel R, Gaddipati GN, Desai PS. Shrestha AK, et al. J Community Hosp Intern Med Perspect. 2025 Jan 6;15(1):58-62. doi: 10.55729/2000-9666.1444. eCollection 2025. J Community Hosp Intern Med Perspect. 2025. PMID: 39867141 Free PMC article.

See all "Cited by" articles

References

1. Reid R, Friedberg JW. Management of marginal zone lymphoma. Oncology (Williston Park). 2013;27(9):840, 842, 844. - PubMed
1. Sriskandarajah P, Dearden CE. Epidemiology and environmental aspects of marginal zone lymphomas. Best Pract Res Clin Haematol. 2017;30(1-2):84-91. - PubMed
1. Cerhan JR, Habermann TM. Epidemiology of marginal zone lymphoma. Ann Lymphoma. 2021;5:1. - PMC - PubMed
1. Swerdlow SH, Campo E, Harris NL, et al. . WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised Fourth Edition. IARC, 2017.
1. Zucca E, Bertoni F. The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. Blood. 2016;127(17):2082-2092. - PubMed

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Marginal zone lymphoma: present status and future perspectives

Affiliations

Marginal zone lymphoma: present status and future perspectives

Authors

Affiliations

Figures

Similar articles

Cited by

References

MeSH terms

LinkOut - more resources

Full Text Sources